Selecta Biosciences Inc acquired Cartesian Therapeutics Inc in a merger, changed its name to Cartesian Therapeutics Inc, and expects to trade under the symbol RNAC beginning on November 14, 2023. The merger is intended to qualify as a tax-free reorganization for U.S. federal income tax purposes. Selecta issued shares of common stock and series A preferred stock to the stockholders of Cartesian in exchange for their shares of capital stock. The company also entered into stockholder support agreements and lock-up agreements with certain officers, directors, and stockholders. Additionally, the company completed a securities purchase agreement with certain investors, and entered into a registration rights agreement with the holders of common stock and series A preferred stock. The company made changes to its management team, with new appointments and resignations. The company also amended its restated certificate of incorporation and filed a certificate of designation for its series A non-voting convertible preferred stock. The company terminated its employee stock purchase plan and approved retention bonuses for certain executive officers. The company expects to file a proxy statement with the SEC for stockholder approval of certain matters related to the merger. The company also made available a presentation and issued a press release regarding the merger and financing.